alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# Official Journal C 254/14 O

| | ISSN 1725-2423 |
| --- | --- |
| Official Journal
  of the European Union | C 254 |
| | |
| English edition | Information and Notices | Volume 4714 October 2004 |

ISSN 1725-2423

Official Journal

of the European Union

C 254

English edition

Information and Notices

Volume 4714 October 2004

---

| Notice No | Contents | page |
| --- | --- | --- |
| | I   Information |
| | Commission |
| 2004/C 254/1 | Euro exchange rates | 1 |
| 2004/C 254/2 | Notice of the impending expiry of certain countervailing measures | 2 |
| 2004/C 254/3 | Notice of the impending expiry of certain anti-dumping measures | 3 |
| 2004/C 254/4 | Notice of the impending expiry of certain countervailing measures | 4 |

Notice No

Contents

page

I   Information

Commission

2004/C 254/1

Euro exchange rates

1

2004/C 254/2

Notice of the impending expiry of certain countervailing measures

2

2004/C 254/3

Notice of the impending expiry of certain anti-dumping measures

3

2004/C 254/4

Notice of the impending expiry of certain countervailing measures

4

---

| | III   Notices |
| --- | --- |
| | Commission |
| 2004/C 254/5 | NO-Oslo: scheduled air services — Invitation to tender — Regional air services in Norway (Narvik (Framnes) – Bodø V-V) – as of 8 March 2005 | 5 |

III   Notices

Commission

2004/C 254/5

NO-Oslo: scheduled air services — Invitation to tender — Regional air services in Norway (Narvik (Framnes) – Bodø V-V) – as of 8 March 2005

5

---

| EN | |
| --- | --- |

EN
Document

Exhibit 10.66





9 November 2021 Mr. Neil Josephson
Interim Chief Medical Officer


Promotion to Chief Medical Officer


Dear Neil,


On behalf of the Board of Directors of Zymeworks Inc. (“Zymeworks”), I am pleased to confirm your promotion to the position of Chief Medical Officer, effective 15 November 2021, and the following changes to your compensation:


									
		Current	New

	Base Salary (USD)	$453,200	$480,000
	Bonus Target	35% + 5% Interim	40%




The increase in base salary will be reflected starting on your 30 November 2021 pay.


Subject to approval of the Board or an authorized committee thereof: (i) you will also receive equity awards worth a total of $2,000,000 USD, to be issued in a 75% stock option and 25% restricted stock unit (RSU) mix on or as soon as practicable after 10 November 2021; and (ii) if prior to the first anniversary of the grant date Zymeworks (A) removes you from the role of Chief Medical Officer or (B) terminates your employment without cause (the effectiveness of such removal or termination, the “Acceleration Date”), the date upon which 25% of such stock options become exercisable and 25% of such RSUs become vested shall be accelerated to such Acceleration Date.


You will be notified via email when your stock option and RSU grants are ready for your review and acceptance in Shareworks.


Your revised compensation is based on a market assessment of Zymeworks’ compensation practices and your contributions to Zymeworks’ goals and ongoing efforts to make Zymeworks a world leader in antibody and protein therapeutics.


All other terms and conditions of your employment contract remain unchanged.


Neil, I want to personally thank you for all your contributions and commitment to Zymeworks’ success. This promotion is well-earned and well-deserved.


Sincerely,


/s/ Ali Tehrani


Dr. Ali Tehrani
President & Chief Executive Officer




Zymeworks Biopharmaceuticals Inc.  |  1215 4th Avenue, Suite 2100, Seattle WA, 98161| zymeworks.com
# Official Journal C 101/2012

| | ISSN 1977-091X
  doi:10.3000/1977091X.C_2012.101.eng |
| --- | --- |
| Official Journal
  of the European Union | C 101 |
| | |
| English edition | Information and Notices | Volume 554 April 2012 |

ISSN 1977-091X

doi:10.3000/1977091X.C_2012.101.eng

Official Journal

of the European Union

C 101

English edition

Information and Notices

Volume 554 April 2012

---

| Notice No | Contents | page |
| --- | --- | --- |
| | II   Information |
| | INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES |
| | European Commission |
| 2012/C 101/01 | Authorisation for State aid pursuant to Articles 107 and 108 of the TFEU — Cases where the Commission raises no objections (1) | 1 |
| 2012/C 101/02 | Non-opposition to a notified concentration (Case COMP/M.6520 — Cinven/George Topco) (1) | 4 |

Notice No

Contents

page

II   Information

INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

2012/C 101/01

Authorisation for State aid pursuant to Articles 107 and 108 of the TFEU — Cases where the Commission raises no objections (1)

1

2012/C 101/02

Non-opposition to a notified concentration (Case COMP/M.6520 — Cinven/George Topco) (1)

4

---

| | IV   Notices |
| --- | --- |
| | NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES |
| | European Commission |
| 2012/C 101/03 | Interest rate applied by the European Central Bank to its main refinancing operations: 1,00 % on 1 April 2012 — Euro exchange rates | 5 |

IV   Notices

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

2012/C 101/03

Interest rate applied by the European Central Bank to its main refinancing operations: 1,00 % on 1 April 2012 — Euro exchange rates

5

---

| | V   Announcements |
| --- | --- |
| | OTHER ACTS |
| | European Commission |
| 2012/C 101/04 | Publication of an application pursuant to Article 6(2) of Council Regulation (EC) No 510/2006 on the protection of geographical indications and designations of origin for agricultural products and foodstuffs | 6 |
| 2012/C 101/05 | Publication of an application pursuant to Article 6(2) of Council Regulation (EC) No 510/2006 on the protection of geographical indications and designations of origin for agricultural products and foodstuffs | 13 |

V   Announcements

OTHER ACTS

European Commission

2012/C 101/04

Publication of an application pursuant to Article 6(2) of Council Regulation (EC) No 510/2006 on the protection of geographical indications and designations of origin for agricultural products and foodstuffs

6

2012/C 101/05

Publication of an application pursuant to Article 6(2) of Council Regulation (EC) No 510/2006 on the protection of geographical indications and designations of origin for agricultural products and foodstuffs

13

---

| | |
| --- | --- |
| | (1)   Text with EEA relevance |

---

(1)   Text with EEA relevance

1

| EN | |
| --- | --- |

EN
First Amendment to Management Continuity Agreement



 Exhibit 10.1 
 FIRST AMENDMENT TO 
 MANAGEMENT CONTINUITY AGREEMENT 

THIS FIRST AMENDMENT (this “Amendment”), dated as of the 13th day of October, 2011, is made to the Management Continuity Agreement
dated the 21st day of December, 2007 (the
“Agreement”), by and between Terrence G. Linnert (the “Executive”) and Goodrich Corporation, a New York corporation (the “Company”). All capitalized terms not defined in this Amendment shall have the meanings ascribed
thereto under the terms of the Agreement, unless otherwise noted. 
 WHEREAS, the Executive and the Company desire to
mutually amend the Agreement. 
 NOW, THEREFORE, in consideration of the mutual covenants contained in this Amendment,
Executive and the Company agree as follows: 
 I. 

Section 2 of the Agreement is hereby deleted and the following inserted in lieu thereof: 

2. Period of Employment. Executive’s “Period of Employment” shall commence on the date on which a Change in
Control occurs and shall end on the date that is 24 months after the date on which such Change in Control occurs. 
 II.

 Section 3(c) of the Agreement is hereby deleted and the following inserted in lieu thereof: 

(c) [Reserved] 

III. 

The first paragraph of Section 5 of the Agreement is hereby deleted and the following inserted in lieu thereof: 

5. Compensation upon Termination of Employment. If, during the Period of Employment, the Company shall terminate
Executive’s employment for any reason (other than for a reason as expressly provided in Section 6(a) hereof), or if Executive shall terminate Executive’s employment for “Good Reason” (as hereinafter defined in
Section 6(b)) then the Company shall be obligated to compensate Executive as follows: 







 IV. 
 Section 6(a)(iv) is hereby amended by deleting “, retirement”. 

V. 
 1. This Amendment
shall be governed by and construed under the laws of the State of North Carolina, without giving effect to the principles of conflicts of laws of such State. 
 2. This Amendment may be executed in one or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument. 

3. Except as amended hereby, the Agreement shall remain in full force and effect. 

IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first written above, to be effective
immediately. 
  

			
	Goodrich Corporation
		
	By:	 	/s/ Marshall O. Larsen        
		 	


  

			
	
		
		 	/s/ Terrence G. Linnert
		 	Terrence G. Linnert



  
 2
EXHIBIT 32




     CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT
     ---------------------------------------------------------------



The certification set forth below is being furnished to the Securities and
Exchange Commission solely for the purpose of complying with Rule 13a-14(b) or
Rule 15d-14(b) of the Securities Exchange Act of 1934 and with Section 1350 of
Chapter 63 of Title 18 of the United States Code. Bartly J. Loethen, the Chief
Executive Officer, Chief Financial Officer and Principal Accounting Officer of
Armitage Mining Corp. hereby certifies that:

1. our Annual Report on Form 10-KSB fully complies with the requirements of
Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. the information contained in our Annual Report on Form 10-KSB fairly
presents, in all material respects, the financial condition and results of
operations of Armitage Mining Corp


Sincerely,

/s/ Michael Potts                         Dated: January 3, 2007
-------------------------------
By: Michael Potts,
Chief Executive Officer,
President, Treasurer, Chief
Financial Officer and Principal
Accounting Officer
NOTE: This order is nonprecedential.

United States Court of Appeals 

for the Federal Circuit ______________________

SOLAS OLED LTD., 

Appellant

v.

KATHERINE K. VIDAL, Under Secretary of 

Commerce for Intellectual Property and 

Director of the United States Patent and 

Trademark Office, 

Intervenor

______________________

2022-1309

______________________

Appeal from the United States Patent and Trademark 

Office, Patent Trial and Appeal Board in No. IPR2019-

01668.

______________________

O R D E R

The parties having so agreed, it is ordered that:

(1) The proceeding is DISMISSED under Fed. R. App. 

P. 42 (b).

Case: 22-1309 Document: 36 Page: 1 Filed: 07/18/2022
2 SOLAS OLED LTD. V. VIDAL 

(2) Each side shall bear their own costs.

FOR THE COURT

July 18, 2022

Date /s/ Peter R. Marksteiner

Peter R. Marksteiner 

Clerk of Court

ISSUED AS A MANDATE: July 18, 2022

Case: 22-1309 Document: 36 Page: 2 Filed: 07/18/2022
Exhibit 31.1

CEO CERTIFICATION

I, Tom Kirchner, as President and Chief Executive Officer, certify that:- I have reviewed this quarterly report on Form 10-QSB of Electronic Systems Technology    Inc.;    
- Based on my knowledge, this quarterly report does not contain any untrue statement of a    material fact or omit to state a material fact necessary to make the statements made, in    light of the circumstances under which such statements were made, not misleading with    respect to the period covered by this quarterly report;    
- Based on my knowledge, the financial statements, and other financial information    included in this quarterly report, fairly present in all material respects the financial    condition, results of operations and cash flows of the registrant as of, and for, the    periods presented in this quarterly report;    
- The registrant’s other certifying officers and I are responsible for establishing    and maintaining disclosure controls and procedures (as defined in Exchange Act Rules    13a-14 and 15d-14) for the registrant and have:        a)designed such disclosure controls and procedures to ensure that material information    relating to the registrant, including its consolidated subsidiaries, is made known to us    by others within those entities, particularly during the period in which this quarterly    report is being prepared;        b)evaluated the effectiveness of the registrant’s disclosure controls and procedures    as of a date within 90 days prior to the filing date of this quarterly report (the    "Evaluation Date"); and        c)presented in this quarterly report our conclusions about the effectiveness of the    disclosure controls and procedures based on our evaluation as of the Evaluation Date;    
- The registrant’s other certifying officers and I have disclosed, based on our most    recent evaluation, to the registrant’s auditor’s and the audit committee of    registrant’s board of directors (or persons performing the equivalent functions):        a)all significant deficiencies in the design or operation of internal controls which could    adversely affect the registrant’s ability to record, process, summarize and report    financial data and have identified for the registrant’s auditors any material    weaknesses in internal controls; and        b)any fraud, whether or not material, that involves management or other employees who have    a significant role in the registrant’s internal controls; and    
- The registrant’s other certifying officers and I have indicated in this quarterly    report whether or not there were significant changes in internal controls or in other    factors that could significantly affect internal control subsequent to the date of our    most recent evaluation, including any corrective actions with regard to significant    deficiencies and material weaknesses. 

Date:  May 7, 2004
/s/ TOM L KIRCHNERTom L. KirchnerPresident and CEO
Dellbith GIRON, Appellant, v. Marisol MELENDEZ-BARRERA, Appellee.

Case No. 5D17-2268

District Court of Appeal of Florida, Fifth District.

Decision filed March 6, 2018

**DECISION WITHOUT PUBLISHED OPINION**

AFFIRMED.
Hubert N. MYERS, Appellant, v. STATE of Florida, Appellee.

No. 1D17-4763

District Court of Appeal of Florida, First District.

February 14, 2018 Rehearing Denied March 22, 2018

**DECISION WITHOUT PUBLISHED OPINION**

AFFIRMED.
EX-10.12


   

  Exhibit 10.12

   

  OUTSIDE DIRECTOR FEE SCHEDULE  

   

  			
	Annual Board Retainer
	-
	$80,000

	 
Non-Executive Chairperson of Board of Directors Fee
	 
-
	 
$75,000/$85,000*

	 
Specially called meeting fee
	 
-
	 
$    1,000

	 
Audit and Risk Management Committee
	 
	 

	 
     Chair Annual Retainer
	 
-
	 
$  20,000

	 
     Member Annual Retainer
	 
-
	 
$  10,000

	 
Compensation and Human Capital Committee 
	 
	 
 

	 
     Chair Annual Retainer
	 
-
	 
$  15,000

	 
     Member Annual Retainer
	 
-
	 
$    7,500

	 
Nominating, Governance  and Corporate Responsibility Committee  
	 
	 

	 
     Chair Annual Retainer
	 
-
	 
$  15,000

	 
     Member Annual Retainer
	 
-
	 
$    7,500



   

  In addition to the fees set forth above, each independent director is granted restricted stock under the 2020 Outside Directors' Stock Award Plan (the "2020 Directors' Plan").  The 2020 Directors' Plan provides each independent director with a grant annually of a number of shares of restricted stock as determined by the Board in its discretion.  For the 2021-2022 directors' year, the Board determined that the value of such restricted stock award would be $100,000 to each Outside Director, with the number of shares of restricted stock to be issued being determined based upon dividing such value by the fair market value of a share of Common Stock on the date of grant.  The Board has determined that following her/his election at the 2022 Annual Meeting, the value of such restricted stock award for the 2022-2023 directors' year will be $110,000 to each Outside Director, with the number of shares of restricted stock to be issued being determined based upon dividing such value by the fair market value of a share of Common Stock on the date of grant.
Exhibit 32.2  CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Our Glass, Inc. (the Company) on Form 10-K for the fiscal year ended December 31, 2009 (the Report), I, Cosmo Palmieri, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: 1) The Report fully complies with the requirement of Section 13(a) or 15 (d) of the Securities Exchange Act of 1934; and 2) The information contained in the Report fairly presents, in all material respects, the Company's financial position and results of operations. February 19, 2010 /s/ Cosmo Palmieri Chief Financial Officer
Second Amendment to Water Gathering and Disposal Agreement




 EXHIBIT 10.19 
 SECOND AMENDMENT TO WATER 
 GATHERING AND DISPOSAL AGREEMENT 
 This Second Amendment to Water Gathering and Disposal Agreement (this “Amendment”) is entered into as of this 30th day of November, 2004, by
and between Robinson’s Bend Operating Company, LLC, a Delaware company, successor in interest to Torch Energy Associates Ltd., a Texas limited partnership (“Producer”), and Everlast Energy LLC, a Delaware company, successor in
interest to Velasco Gas Company Ltd., a Texas limited partnership (“Gatherer”). 
 RECITALS: 
 A. Reference is herein made to (i) that certain Water Gathering and Disposal Agreement entered into as of August 9, 1990, by and between Producer’s
and Gatherer’s respective predecessors in interest (the “Original Agreement”), and (ii) that certain First Amendment to Water Gathering and Disposal Agreement entered into as of October 1, 1993, by and between such parties (the
“First Amendment;” the Original Agreement, as amended by the First Amendment, is herein called the “Agreement”). Capitalized terms used herein but not otherwise defined herein shall have the respective meanings assigned to them
in the Agreement. 
 B. The parties hereto deem it in their mutual best interests to amend the Agreement as provided herein. 
 AGREEMENT: 
 NOW, THEREFORE, in
consideration of the premises and of the mutual promises and agreements contained herein and in the Agreement, the receipt and sufficiency of which are hereby acknowledged, Gatherer and Purchaser agree as follows: 
 1. Agreement to Section 3.1. Section 3.1 of the Agreement is hereby amended in its entirely to read as follows: 
 “3.1 Producer shall pay Gatherer a fee of $0.53 per barrel for gathering, separation and disposal of water until the Trust
terminates, at which point Producer shall pay Gatherer a fee of $1.00 per barrel for gathering, separation and disposal of water.” 
 2.
Ratification. The Agreement, as amended by this Amendment, is hereby ratified and confirmed in all respects. 
 [REMAINDER OF PAGE
INTENTIONALLY BLANK] 








 IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first above written.

  

					
	GATHERER:
	
	 ROBINSON’S BEND OPERATING COMPANY, LLC
 (as successor in interest to
 Torch Energy Associates Ltd.)

			
		 	By:	 	 /s/ DENNIS HAMMOND

		 	Name:	 	DENNIS HAMMOND
		 	Title:	 	VP
	
	PRODUCER:
	
	 EVERLAST ENERGY LLC
 (as successor in
interest to
 Velasco Gas Company Ltd.)

			
		 	By:	 	 /s/ DENNIS HAMMOND

		 	Name:	 	DENNIS HAMMOND
		 	Title:	 	VP


  

 - 2 -
```

[Congressional Bills 112th Congress]
[From the U.S. Government Publishing Office]
[S. 2632 Introduced in Senate (IS)]

112th CONGRESS
  2d Session
                                S. 2632

   To extend the temporary suspension of duty on Cloquintocet-mexyl.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                              May 7, 2012

 Mr. Nelson of Nebraska introduced the following bill; which was read 
             twice and referred to the Committee on Finance

_______________________________________________________________________

                                 A BILL

 
   To extend the temporary suspension of duty on Cloquintocet-mexyl.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. CLOQUINTOCET-MEXYL.

    (a) In General.--Heading 9902.12.57 of the Harmonized Tariff 
Schedule of the United States (relating to Cloquintocet-mexyl) is 
amended by striking the date in the effective period column and 
inserting ``12/31/2015''.
    (b) Effective Date.--The amendment made by subsection (a) applies 
to goods entered, or withdrawn from warehouse for consumption, on or 
after the 15th day after the date of the enactment of this Act.
                                 <all>
```
Shane BURNS, Appellant, v. STATE of Florida, Appellee.

Case No. 5D17-944

District Court of Appeal of Florida, Fifth District.

Decision filed February 6, 2018

**DECISION WITHOUT PUBLISHED OPINION**

AFFIRMED.
Bryan A. SPELLERS, Appellant, v. STATE of Florida, Appellee.

Case No. 5D17-2896

District Court of Appeal of Florida, Fifth District.

Decision filed December 12, 2017

**DECISION WITHOUT PUBLISHED OPINION**

AFFIRMED.
Exhibit 4.9

       

      CERTIFICATE OF AMENDMENT

      TO THE

      RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED,

      OF

      HESKA CORPORATION

       

      Heska Corporation (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify:

      

      

      	1.	
              This Certificate of Amendment to the Corporation’s Restated Certificate of Incorporation, as amended (the “Certificate”), has been duly adopted in accordance with the provisions of Section 242 of the DGCL.

            


      

      

      	2.	
              This Certificate of Amendment to the Certificate amends Article IV of the Certificate by deleting the existing Paragraph A of Article IV in its entirety and substituting therefor a new Paragraph A of Article IV, to read in its entirety
                as follows:

            


      

      

      Authorized Stock. The total authorized stock of the Corporation, which shall be an aggregate of 42,500,000 shares, shall consist of three classes: (i) a first class consisting of 20,000,000 shares of Traditional
        Common Stock having a par value of $0.01 per share (the “Original Common Stock”); (ii) a second class consisting of 20,000,000 shares of Public Common Stock having a par value of $0.01 per share (the “Common Stock” or “NOL Restricted Common Stock”
        and, together with the Original Common Stock, the “Common Stock Securities”); and (iii) a third class consisting of 2,500,000 shares of Preferred Stock having a par value of $0.01 per share (the “Preferred Stock”).

      

      

      	3.	
              This Certificate of Amendment to the Certificate shall become effective at the time this Certificate of Amendment to the Certificate is filed with the Secretary of State of the State of Delaware.

            


      

      

      IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to the Certificate to be executed by a duly authorized officer on this 22nd day of November, 2021.

      

      

      
        	 	
                Heska Corporation

              
	 	
                By:

              	
                /s/ Kevin Wilson

              
	 	
                Name:

              	
                Kevin Wilson

              
	 	
                Title:

              	
                President, Chief Executive Officer